Tune raises $175M for hepatitis B medicine, epigenetic research
Genetic medicine startup Tune Therapeutics has raised another $175 million to develop therapies capable of “tuning” genes to treat disease, rather than editing them by cutting or replacing DNA directly. Tune disclosed the Series B round on Sunday, the eve …